Background and Objectives
Patients with metastatic triple-negative breast cancer (mTNBC) have poor prognosis and survival outcomes. Sacituzumab govitecan (SG) has shown significant survival benefits, but its cost-effectiveness still needs evaluation. The present study aimed to evaluate the cost-effectiveness of SG versus physician’s choice of treatment in patients with mTNBC in the context of the Spanish National Health system.
Methods
A partitioned survival model using data from the ASCENT clinical trial was developed to assess lifetime costs and benefits for patients with mTNBC. Quality-adjusted life years (QALYs) were employed as a measure of effectiveness. Data on costs and subsequent treatment were gathered from Spanish sources and validated by health professionals. Analyses were performed from the perspective of the Spanish NHS over lifetime.
Results
The average health cost of treating patients with SG for 120 months was €94,335 compared with €7926 for treatment of physician choice. Effectiveness pertaining to the SG group was 1.05 QALY compared with 0.48 QALY in the control group. The incremental cost-utility ratio (ICUR) was €151,716/QALY. Univariate sensitivity analyses produced ICURs that ranged between 102,764 and 216,077 €/QALY.
Conclusions
Despite clinical benefits of SG in patients with mTNBC, its cost exceeds accepted thresholds. The findings suggest a need for price reassessment within the Spanish National Health System to ensure value-based, equitable access.